Kaufman Jonathan H's Form 4 filing
Lipella Pharmaceuticals Inc. (LIPO) · filed May 15, 2024
- Accession no.
- 0001753926-24-000984
- Filed
- May 15, 2024
- Trade date
- May 14, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $7.60K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Kaufman Jonathan HCIK 0001959250 | Director, Officer (See remarks below.), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Reflects the weighted average price of the shares of Common Stock purchased on the open market in multiple transactions on May 14, 2024 at prices ranging from $0.7552 to $0.76 per share, inclusive. The amount reflected has been rounded to 3 decimal points.
Referenced by the price of 1 transaction in Table I.
- F3
The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of such shares of Common Stock purchased at each separate price within such range.
Referenced by the price of 1 transaction in Table I.
Remarks
President, Chief Executive Officer, Secretary, Treasurer, and Chairman of the Board of Directors